Back to top
more

Artivion (AORT)

(Delayed Data from NYSE)

$32.15 USD

32.15
196,098

+0.09 (0.28%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $32.16 +0.01 (0.03%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of +6.17% and +3.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Lags Q1 Earnings Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?

by Zacks Equity Research

Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Do Options Traders Know Something About Artivion (AORT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Artivion (AORT) stock based on the movements in the options market lately.

Zacks Equity Research

Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround

by Zacks Equity Research

Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Artivion (AORT) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of -100% and 3.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sensus Healthcare (SRTS) Moves 19.9% Higher: Will This Strength Last?

by Zacks Equity Research

Sensus Healthcare (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.87% and 1.31%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Best Momentum Stocks to Buy for January 7th

by Zacks Equity Research

NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 7th

by Zacks Equity Research

AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024.

Zacks Equity Research

Artivion (AORT) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 300% and 0.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -25% and 31.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 133.33% and 0.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of 15.79% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -11.54% and 0.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

by Zacks Equity Research

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Zacks Equity Research

Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Are Medical Stocks Lagging Artivion (AORT) This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Derek Lewis headshot

3 Buy-Rated Small Caps Flexing Big Growth

by Derek Lewis

Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Zacks Equity Research

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.